RxDoctor Payments Data

Daniel Coden, MD

Ophthalmology · la Jolla, CANPI 1942317508

Payments from drug & device makers

$7,629in general payments, 2019–2025

Across 71 payments — averaging $107.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$5K
  • Biotissue Holdings Inc.$1K
  • Amgen$412
  • AbbVie$378
  • Johnson & Johnson Surgical Vision, Inc.$344
  • Bausch & Lomb Americas Inc.$216
  • plus $373 from 9 others

What the payments were for

  • Speaking & faculty fees$4,40058%
  • Travel & lodging$1,22316%
  • Food & beverage$1,97426%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,629 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$129,118
Medicare patients
455
Services billed
1,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast18$18,468
MieboPerfluorohexyloctane/Pf17$16,834
RestasisCyclosporine11$11,330
LumiganBimatoprost14$10,255
Brimonidine Tartrate22$3,747
SimbrinzaBrinzolamide/Brimonidine Tart14$3,603
Latanoprost230$3,059
Travoprost17$2,489
Prednisolone Acetate80$2,089
Timolol Maleate141$1,705
MoxifloxacinMoxifloxacin Hcl84$1,210
Ketorolac Tromethamine92$1,054
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat44$993
Tobramycin-DexamethasoneTobramycin/Dexamethasone14$457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$216$35,30235 claims
AbbVieRestasis, Lumigan$378$21,58525 claims
AlconSimbrinza$4,698$3,60314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →